Organogenesis (ORGO) Projected to Post Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is projected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Organogenesis to post earnings of ($0.35) per share and revenue of $54.2740 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.08). Organogenesis had a negative net margin of 0.84% and a positive return on equity of 9.63%. The firm had revenue of $37.23 million during the quarter, compared to analysts’ expectations of $43.26 million.

Organogenesis Trading Up 1.3%

Shares of ORGO opened at $2.37 on Wednesday. Organogenesis has a 52-week low of $2.04 and a 52-week high of $7.08. The stock has a market cap of $304.97 million, a PE ratio of -12.47 and a beta of 1.34. The firm’s fifty day moving average is $2.45 and its two-hundred day moving average is $2.79. The company has a quick ratio of 3.16, a current ratio of 3.53 and a debt-to-equity ratio of 0.05.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. UBS Group set a $3.00 price target on shares of Organogenesis in a research note on Thursday, May 28th. BTIG Research downgraded shares of Organogenesis from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Truist Financial started coverage on shares of Organogenesis in a research note on Thursday, May 28th. They issued a “hold” rating and a $3.00 target price on the stock. Wall Street Zen upgraded Organogenesis from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. Finally, Weiss Ratings lowered Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.75.

Institutional Investors Weigh In On Organogenesis

A number of hedge funds have recently modified their holdings of the company. First Light Asset Management LLC purchased a new position in Organogenesis during the second quarter worth about $24,804,000. Deutsche Bank AG grew its stake in shares of Organogenesis by 0.4% in the 4th quarter. Deutsche Bank AG now owns 3,297,631 shares of the company’s stock valued at $17,082,000 after buying an additional 13,301 shares during the period. Geode Capital Management LLC increased its holdings in shares of Organogenesis by 3.6% during the 4th quarter. Geode Capital Management LLC now owns 1,786,978 shares of the company’s stock worth $9,259,000 after buying an additional 62,346 shares during the last quarter. Norges Bank purchased a new stake in shares of Organogenesis during the 4th quarter valued at approximately $5,686,000. Finally, Bank of America Corp DE raised its position in shares of Organogenesis by 27.2% during the 3rd quarter. Bank of America Corp DE now owns 611,685 shares of the company’s stock valued at $2,581,000 after buying an additional 130,875 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.